( August 13, 2026, 14:44 GMT | Official Statement) -- MLex Summary: Plaintiffs bringing US antitrust claims against Ranbaxy over the drug Lipitor lack antitrust standing, and thus are inadequate class representatives, according to an appeals court. The Court of Appeals for the Third Circuit affirmed a summary judgment, saying that while the Food and Drug Administration would have endeavored to approve a generic Lipitor product from Ranbaxy if the company hadn’t agreed to stay out of the market until November 2011, plaintiffs have not shown that the FDA would have succeeded in doing so. “[A]lthough it is perhaps ‘possible’ that the FDA could have acted more quickly, it is ‘also certainly possible’ that it would not have, and ‘[w]ithout more specific or concrete evidence’ that the FDA would have granted earlier approval, plaintiffs cannot establish antitrust standing and summary judgment in favor of Ranbaxy was appropriate,” Circuit Judge Patty Schwartz wrote in the opinion.See attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.